Table 2.
Association of CC16 mRNA Expression Levels in Bronchial Epithelial Cells with Asthma Susceptibility and Asthma Severity
| SARP Cross-sectional Cohort Microarray mRNA (n = 155) | Nonsmoking Control Subjects (n = 27) | Nonsmoking Asthma* (n = 128) | OR (P Value)† | Nonsevere Asthma‡ (n = 78) | Severe Asthma‡ (n = 50) | OR (P Value)† |
|---|---|---|---|---|---|---|
| CC16 mRNA expression levels (log2) | 18.9 ± 0.36 | 17.9 ± 1.14 | 0.10 (<0.0001) | 18.2 ± 0.86 | 17.5 ± 1.36 | 0.55 (0.0049) |
| SARP Longitudinal Cohort RNAseq (n = 156) | Nonsmoking Control Subjects (n = 42) | Nonsmoking Asthma* (n = 114) | OR (P value)† | Nonsevere Asthma‡ (n = 52) | Severe Asthma‡ (n = 62) | OR (P value)† |
|---|---|---|---|---|---|---|
| CC16 mRNA expression levels (ln) | 16.3 ± 0.44 | 15.4 ± 1.01 | 0.14 (<0.0001) | 15.6 ± 0.97 | 15.1 ± 1.00 | 0.67 (0.058) |
Definition of abbreviations: ln = natural logarithm; log2 = logarithm base 2; OR = odds ratio; RNAseq = RNA sequencing; SARP = Severe Asthma Research Program.
For the longitudinal cohort, nonsmokers were never-smokers or previous smokers with less than 5 to 10 pack-years of tobacco use, depending on age. For the cross-sectional cohort, nonsmokers were never-smokers or previous smokers with less than 5 pack-years of tobacco use.
OR and P value were generated using a logistic regression model adjusted for age, sex, body mass index, race, and batch effect.
Asthma severity (nonsevere or severe asthma) was on the basis of American Thoracic Society–European Respiratory Society criteria (29). CC16 mRNA expression levels were log2- and ln-transformed in the SARP cross-sectional cohort and longitudinal cohort, respectively.